Dmitry Balyasny Balyasny Asset Management
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPCX
SpaceX
SPCX
|
+$577M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$538M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
+$517M |
| 4 |
Texas Instruments
TXN
|
+$413M |
| 5 |
Roku
ROKU
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HOLX
Hologic
HOLX
|
+$357M |
| 2 |
Meta Platforms (Facebook)
META
|
+$326M |
| 3 |
Johnson Controls International
JCI
|
+$303M |
| 4 |
Applied Materials
AMAT
|
+$285M |
| 5 |
CTRA
Coterra Energy
CTRA
|
+$285M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.69% |
| 2 | Industrials | 9.96% |
| 3 | Consumer Discretionary | 8.03% |
| 4 | Healthcare | 7.46% |
| 5 | Financials | 6.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1701
CALL
State Street SPDR EURO STOXX 50 ETF
FEZ
$4.54B
| $2.21M | ﹤0.01% |
+32,200
| New | +$2.15M |
|
1702
Corcept Therapeutics
CORT
$13.2B
| $2.2M | ﹤0.01% |
+25,349
| New | +$1.53M |
|
1703
CALL
Agnico Eagle Mines
AEM
$109B
| $2.2M | ﹤0.01% |
14,200
-3,000
| -17% | -$556K |
|
|
HSAI
1704
Hesai Group
HSAI
$3B
| $2.2M | ﹤0.01% |
120,755
-374
| -0.3% | -$7.65K |
|
1705
Scholastic
SCHL
$757M
| $2.19M | ﹤0.01% |
47,698
+30,927
| +184% | +$1.27M |
|
1706
CALL
Allstate
ALL
$64.2B
| $2.19M | ﹤0.01% |
9,200
+7,200
| +360% | +$1.56M |
|
1707
Hamilton Insurance Group
HG
$3.45B
| $2.18M | ﹤0.01% |
64,242
-49,254
| -43% | -$1.54M |
|
1708
Fortinet
FTNT
$113B
| $2.17M | ﹤0.01% |
14,127
-12,934
| -48% | -$1.49M |
|
1709
PUT
EQT Corp
EQT
$33.6B
| $2.17M | ﹤0.01% |
40,800
+29,300
| +255% | +$1.64M |
|
1710
CALL
AbbVie
ABBV
$468B
| $2.16M | ﹤0.01% |
8,600
+4,500
| +110% | +$968K |
|
1711
Duolingo
DUOL
$6.84B
| $2.16M | ﹤0.01% |
+18,766
| New | +$2.05M |
|
1712
CALL
CAVA Group
CAVA
$8.6B
| $2.14M | ﹤0.01% |
27,300
-1,800
| -6% | -$151K |
|
1713
World Kinect Corp
WKC
$1.84B
| $2.14M | ﹤0.01% |
64,927
-57,584
| -47% | -$1.6M |
|
1714
Albemarle
ALB
$16.9B
| $2.14M | ﹤0.01% |
15,826
+13,978
| +756% | +$2.47M |
|
1715
CALL
DaVita
DVA
$11.1B
| $2.14M | ﹤0.01% |
+9,600
| New | +$1.74M |
|
1716
Ziff Davis
ZD
$1.92B
| $2.13M | ﹤0.01% |
+40,753
| New | +$1.84M |
|
1717
CALL
FIVE9
FIVN
$2.45B
| $2.13M | ﹤0.01% |
100,000
| – | – |
|
|
ARIS
1718
Aris Mining
ARIS
$4.31B
| $2.13M | ﹤0.01% |
142,978
-1,136
| -0.8% | -$20.4K |
|
1719
Atkore
ATKR
$3.16B
| $2.13M | ﹤0.01% |
28,014
-18,649
| -40% | -$1.4M |
|
1720
XPeng
XPEV
$11.7B
| $2.13M | ﹤0.01% |
+160,571
| New | +$2.55M |
|
1721
PUT
Abercrombie & Fitch
ANF
$4.84B
| $2.12M | ﹤0.01% |
23,600
| – | – |
|
1722
CALL
Cigna
CI
$73.3B
| $2.12M | ﹤0.01% |
+7,700
| New | +$2.18M |
|
1723
CALL
Upstart Holdings
UPST
$2.95B
| $2.12M | ﹤0.01% |
59,800
-27,000
| -31% | -$832K |
|
1724
Relay Therapeutics
RLAY
$4.26B
| $2.11M | ﹤0.01% |
112,989
-2,926,190
| -96% | -$42.5M |
|
1725
Forward Air
FWRD
$612M
| $2.11M | ﹤0.01% |
+156,471
| New | +$2.33M |
|
Similar funds
Dmitry Balyasny's Q2 2026 Portfolio in Review
As of Q2 2026, Dmitry Balyasny held 3,665 positions worth $80.2B, up 4% from $77.1B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Dmitry Balyasny withdrew a net $7.14B in Q2 2026, closing 734 positions and reducing 995 holdings. Its most notable exit was Hologic, an estimated $357M position sold in full.
By sector, the portfolio is most concentrated in Technology at 13% of assets, up from 9.7% a quarter earlier, followed by Industrials and Consumer Discretionary.
Against the trend, Dmitry Balyasny opened a new position in SpaceX worth $581M.
- Dmitry Balyasny's largest Q2 2026 buy was SpaceX: 3,397,642 shares worth $581M.
- Dmitry Balyasny added most to State Street SPDR S&P 500 ETF Trust in Q2 2026, an estimated $538M increase.
- Dmitry Balyasny's biggest Q2 2026 reduction was Meta Platforms (Facebook), cutting an estimated $326M.
- Dmitry Balyasny fully exited Hologic in Q2 2026, selling an estimated $357M.
- Dmitry Balyasny's ten largest holdings make up 14% of its $80.2B portfolio in Q2 2026.
- Dmitry Balyasny opened 834 new positions and closed 734 in Q2 2026.
- Dmitry Balyasny's portfolio value rose 4% quarter-over-quarter to $80.2B.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.